<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00656357</url>
  </required_header>
  <id_info>
    <org_study_id>SYN117-CL01</org_study_id>
    <nct_id>NCT00656357</nct_id>
  </id_info>
  <brief_title>Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers</brief_title>
  <official_title>A Human Laboratory Assessment of the Safety and Potential Efficacy of SYN117 (Nepicastat) in Cocaine-dependent Volunteers Receiving Cocaine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotie Therapies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotie Therapies Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the potential interaction and subjective effects between intravenous
      cocaine and SYN117 in non-treatment seeking cocaine dependant subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the safety of treatment with SYN117 in cocaine-dependent volunteers by measuring hemodynamic and subjective effects of administration of ascending doses of cocaine(10mg, 20mg, 40mg)and placebo during treatment with ascending doses of SYN117.</measure>
    <time_frame>inpatient 14 days with 2 week outpatient follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine tolerability by measuring adverse events</measure>
    <time_frame>inpatient 14 days, 2 weeks post followup visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine subjective effects produced by self administration of cocaine or placebo</measure>
    <time_frame>Days 4, 8, 12 and 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the effect of SYN117 of the pharmacokinetics of IV cocaine</measure>
    <time_frame>Days 3 and 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine if any baseline measures of impulsivity or drug use severity predict efficacy of SYN117 in reducing subjective effects of cocaine</measure>
    <time_frame>Days 4, 8 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SYN117 placebo and Ascending doses of cocaine (10, 20, 40 mg) and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending doses of SYN117 (placebo, 80 mg, 160 mg) and ascending doses of cocaine (10 mg, 20 mg, 40 mg) and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYN117 Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYN117 80 mg</intervention_name>
    <description>SYN117 80 mg</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYN117 160 mg</intervention_name>
    <description>SYN117 160 mg</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cocaine 10mg</intervention_name>
    <description>IV Cocaine 10mg</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cocaine 20mg</intervention_name>
    <description>IV Cocaine 20mg</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cocaine 40mg</intervention_name>
    <description>IV Cocaine 40mg</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>IV Cocaine Placebo</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non treatment seeking cocaine dependent

          -  English speaking

          -  meet DSM IV TR criteria for cocaine dependence

          -  pulse 50-90bpm

          -  systolic BP 85-140 mmHg

          -  diastolic BP 45-90 mmHg

          -  essentially normal liver and kidney function blood tests

          -  ECG normal

          -  sign informed consent

          -  negative urine pregnancy test at screening and admission

        Exclusion Criteria:

          -  history or evidence of seizure disorder or brain injury

          -  previous medically adverse reaction to cocaine, including loss of consciousness, chest
             pain or epileptic seizure

          -  neurological disorders, organic brain disease, dementia

          -  psychiatric disorders such as psychosis, schizophrenia, bipolar disorder, major
             depression

          -  history of suicide attempts within past 3 months or suicidal ideation/plan

          -  history of clinically significant heart disease or hypertension

          -  family history in 1st degree relatives of early cardiovascular morbidity or mortality

          -  untreated or unstable medical conditions

          -  positive HIV test

          -  pregnant or nursing

          -  have asthma or are currently using alpha, beta agonists or theophylline or other
             sympathomimetics

          -  test positive for other drugs of abuse with the exception of cocaine, cocaine
             metabolites or marijuana

          -  any other illness, condition or use of psychotropic medications which preclude
             safe/successful completion of the study

          -  currently on parole
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Bandak, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Biotie Therapies Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>F. Gerald Moeller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UTSW-Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathryn Cunningham, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTMB-Galveston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Medical Branch (UTMB)</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2008</study_first_posted>
  <disposition_first_submitted>December 3, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>December 3, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 7, 2009</disposition_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

